The 2026 DRC Ebola outbreak is, analytically, two simultaneous events. At the surface level it is a humanitarian emergency of serious scale: 4,000-plus confirmed cases, nearly 1,800 deaths, spread into displacement camps in Ituri province where transmission conditions approach worst-case. At the structural level it is the first live test of a preparedness architecture built for a different Ebola species. The two certified treatments — Ebanga (ansuvimab-kkft) and Inmazeb — were designed and approved against Zaire ebolavirus, the species responsible for the 2014–2016 West Africa epidemic. Bundibugyo ebolavirus targets different surface glycoproteins; clinical efficacy of both drugs against it has not been established. The gap is not a failure of negligence — it is the visible cost of a rational prioritisation decision. Following the 2014–2016 emergency, the largest Ebola outbreak in recorded history, CEPI and partner institutions directed deep funding toward Zaire ebolavirus coverage because that was where the evidence of severity was concentrated. Bundibugyo's prior record — Uganda 2007, DRC 2012 — was smaller and did not generate comparable institutional pressure. The investment case was defensible. The portfolio exposure it created is now active. The Wake Desk examines the structure that produced the gap, what the case fatality rate is telling us about the distance between preparation and adaptation, and what the current response can and cannot do within the constraints the portfolio set.
The DRC ebolavirus outbreak of 2026 has surpassed 4,000 confirmed cases and 1,800 deaths. Established It has spread into displacement camps in Ituri province, where population density and severely compromised health infrastructure accelerate transmission. Established The humanitarian scale is not in dispute. The analytical question that defines this outbreak is different: the pathogen driving it is Bundibugyo ebolavirus — a species for which no certified treatment was designed, trialled, or approved.
Why Bundibugyo Changes the Calculus
Ebolavirus is a genus of six distinct species, not a single disease with variants. The two certified treatments in the international response toolkit — Ebanga (ansuvimab-kkft) and Inmazeb (atoltivimab, maftivimab, odesivimab) — were developed and approved against Zaire ebolavirus, the species responsible for the 2014–2016 West Africa epidemic and the 2018–2020 Kivu outbreak in DRC. Established Both drugs function by targeting surface glycoproteins specific to Zaire ebolavirus; those glycoproteins differ structurally in Bundibugyo, and clinical efficacy against it has not been established. Established Responders therefore cannot apply the standard first-line therapeutic protocol with the confidence that has anchored every Zaire outbreak response since 2014. This is not a variant problem — the pathogen has not mutated away from a treatment it was once susceptible to. It was never the target. The distinction is species-level, and it is the analytical hinge of the current crisis.
The practical difference in a response setting is this: in every Zaire outbreak since 2014, treatment teams could draw on a certified therapeutic protocol and a documented efficacy record. Clinical teams in Ituri cannot. They are working with supportive care, experimental protocols adapted from Zaire evidence, and — as of the WHO trial launched in August — a vaccine candidate with no prior large-cohort safety and efficacy data for this species. The 2007 Uganda Bundibugyo outbreak produced a case fatality rate of approximately 25 per cent with only supportive care available. The current 2026 DRC outbreak is running at approximately 45 per cent — 1,800 deaths against 4,000 confirmed cases. The gap between those two figures is not attributable to a single cause, and displacement camp conditions in Ituri provide significant additional pressure. But the absence of a certified first-line therapeutic is a contributing factor that cannot be disaggregated from the others. Assessed
The Case Fatality Rate as Evidence
The current case fatality rate deserves its own analytical attention because it is the only real-time measure of how the treatment gap interacts with outbreak conditions. At approximately 45 per cent — 1,800 deaths from 4,000 confirmed cases — the 2026 DRC rate substantially exceeds Bundibugyo's historical CFR in Uganda (approximately 25 per cent) and approximates the worst outcomes recorded in Zaire outbreaks prior to the availability of targeted therapeutics. Assessed
Three factors are compounding simultaneously. The first is the absence of a certified therapeutic: responders cannot apply the standard protocol, and experimental alternatives carry uncertainty in both dosing and efficacy against this species. The second is camp conditions: Ituri's displacement population has the density and infrastructure deficits that accelerate transmission and delay isolation, raising the effective CFR above what clinical management alone would predict. The third is health system attrition: MSF's operational brief notes severely compromised health infrastructure in the affected zone, meaning a larger proportion of patients reach clinical care only after the illness has advanced beyond the window where early intervention is most effective. Established
The CFR is not a clean proxy for the treatment gap in isolation. It is a proxy for the combination of species-level preparation failure, conflict-zone displacement, and health system collapse acting simultaneously. What it cannot tell us is the precise weight of each factor — that separation requires a controlled comparison this outbreak does not provide. What it does tell us is that the current outcome is significantly worse than Bundibugyo's historical record, in conditions that were predictably more adverse, and that the preparedness system is operating without its most effective tool. Assessed
The Portfolio Logic That Produced the Gap
The absence of a Bundibugyo-certified treatment is the predictable output of a rational, but now visibly limited, investment prioritisation. Assessed — High confidence Following the 2014–2016 West Africa epidemic — 28,616 cases, more than 11,000 deaths, caused by Zaire ebolavirus — the Coalition for Epidemic Preparedness Innovations and partner institutions directed the bulk of Ebola countermeasure funding toward Zaire ebolavirus coverage. The 2018–2020 Kivu outbreak reinforced that allocation logic. Bundibugyo's prior record — Uganda in 2007, DRC in 2012 — was smaller in scale and did not produce comparable institutional pressure. The investment case for deep Zaire coverage was strong; the case for comparable investment in less-prevalent species competed for finite resources and lost. Assessed — High confidence
The WHO R&D Blueprint — the framework established after the 2014 Ebola and 2015 Zika emergencies to prioritise epidemic preparedness research — lists Zaire ebolavirus as a priority pathogen; Bundibugyo does not appear as a separate development target in the current priority list. That listing reflects the same severity-weighted logic that shaped CEPI's funding allocations. The framework worked as designed: it concentrated resources where the evidence of worst-case severity was strongest. Its output is a preparedness portfolio that is robust where the historical record is densest, and structurally exposed to the six-species genus it only partially covers. The result is not a failure of neglect. It is the visible cost of a choice — the same choice any institution with finite resources and an accountability structure built around the last emergency would make. Assessed
What the System Is Doing Now
The institutional response is accelerating within the constraints the portfolio created. The United States pledged $242 million on 5 August 2026 — the largest single-country financial commitment of the outbreak. Established The WHO has launched a vaccine trial specifically targeting Bundibugyo ebolavirus, operating on compressed timelines that characterise mid-crisis development. Established MSF is operational in Ituri, adapting isolation and care protocols in the absence of a standard therapeutic countermeasure. Established The ECDC has issued an advisory for European member states. Established
The vaccine trial timeline matters because it determines whether any certified countermeasure for Bundibugyo ebolavirus will be available before this outbreak ends. Standard Phase III trial timelines run 18 to 24 months from initiation through to regulatory review. Emergency use authorisation frameworks can compress that window significantly — the COVID-19 vaccine precedent demonstrated how far — but efficacy and safety data still require a minimum observation period that the biology of a clinical trial cannot eliminate. The $242 million US pledge can fund expansion of supportive care capacity and trial infrastructure; it cannot compress the observation window. The system is responding as fast as it can within the constraints of what it did not prepare for. Responding fast within those constraints is not the same as being prepared. The difference between those two conditions is currently visible in the case fatality rate.